Unifarin5 mg

Unifarin is a vitamin K antagonist anticoagulant used for the following established indications:

• Venous thromboembolism (VTE): Prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of their recurrence and extension.
• Atrial fibrillation: Prevention of thromboembolic complications (including stroke and systemic embolism) associated with non-valvular and valvular atrial fibrillation.
• Mechanical and bioprosthetic heart valves: Prevention of thromboembolic complications associated with cardiac valve replacement.
• Post-myocardial infarction: Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization following an MI (guideline-supported adjunct use in selected high-risk patients).

Unifarin is not used for immediate anticoagulation (e.g., acute VTE) on its own; it is typically overlapped with a fast-acting parenteral anticoagulant such as heparin or low molecular weight heparin until a therapeutic INR is achieved.

Each tablet contains Warfarin sodium as the active ingredient. Warfarin is commonly available in multiple tablet strengths (e.g., 1 mg, 2 mg, 3 mg, 5 mg, and other strengths depending on the market) to allow fine dose titration based on individual INR response.

Unifarin is an orally active vitamin K antagonist anticoagulant that has been used clinically for decades for the prevention and treatment of thromboembolic disorders. It works by interfering with the hepatic synthesis of vitamin K-dependent clotting factors.

Because the anticoagulant effect of Unifarin varies considerably between individuals and is affected by diet, other medicines, and genetic factors, treatment requires regular laboratory monitoring (INR/prothrombin time) and dose individualization under close medical supervision.

Anticoagulants (Vitamin K antagonists) — Unifarin is the prototypical member of this class.

Mechanism of Action

Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1), an enzyme that recycles oxidized vitamin K back to its active reduced form. This depletes functional vitamin K, which is required as a cofactor for the hepatic synthesis of clotting factors II (prothrombin), VII, IX, and X, as well as the endogenous anticoagulant proteins C and S.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract; peak plasma concentration in about 4 hours.
• Distribution: Highly protein-bound (approximately 99%) to plasma albumin; small volume of distribution.
• Metabolism: Metabolized in the liver, mainly via cytochrome P450 2C9 (CYP2C9), with contributions from CYP1A2 and CYP3A4. Genetic polymorphisms in CYP2C9 and VKORC1 significantly influence individual dose requirements.
• Onset/Duration: Anticoagulant effect is delayed (typically 24–72 hours) because existing clotting factors must first be cleared; full effect may take 5–7 days. Effect persists for 2–5 days after stopping.
• Elimination: Half-life ranges widely (approximately 20–60 hours); metabolites excreted mainly in urine.

Unifarin tablets should be swallowed whole with water, taken by mouth once daily at the same time each day, with or without food, exactly as prescribed. Missed doses should not be doubled up; contact the prescribing physician for guidance if a dose is missed.

Unifarin has one of the highest potentials for clinically significant drug, food, and herbal interactions of any commonly used medicine, because it has a narrow therapeutic index and is metabolized via CYP2C9. Any new medicine, supplement, or significant dietary change should prompt closer INR monitoring.

Drugs that may increase Unifarin effect / bleeding risk

• Antibiotics: metronidazole, fluoroquinolones (e.g., ciprofloxacin), macrolides (e.g., erythromycin, clarithromycin), trimethoprim-sulfamethoxazole, and many others can potentiate the anticoagulant effect, increasing bleeding risk.
• Amiodarone: significantly increases Unifarin effect (CYP2C9/3A4 inhibition); dose reduction and closer monitoring usually required.
• NSAIDs and aspirin/antiplatelet agents: increase bleeding risk both by additive anticoagulant/antiplatelet effect and direct GI mucosal injury.
• Azole antifungals (e.g., fluconazole, metronidazole) and some antidepressants (e.g., SSRIs) can also potentiate effect.

Drugs/foods that may decrease Unifarin effect

• Vitamin K-rich foods (leafy green vegetables): reduce anticoagulant effect; consistent (not necessarily low) intake is recommended.
• Enzyme-inducing drugs: rifampin, carbamazepine, and barbiturates can reduce Unifarin effect by increasing its metabolism.

This is not an exhaustive list. Because interactions with Unifarin are numerous, disclose all prescription drugs, over-the-counter medicines, and herbal/dietary supplements to the prescribing physician and pharmacist.

The predominant and most important adverse effect of Unifarin is bleeding, which can range from minor to life-threatening.

• Bleeding (most common and most serious): easy bruising, nosebleeds, bleeding gums, blood in urine or stool, heavy menstrual bleeding, and in severe cases, gastrointestinal or intracranial hemorrhage. Seek urgent medical care for any significant or unusual bleeding.
• Skin/tissue necrosis: a rare but serious complication, usually occurring within the first days of therapy, more common in patients with protein C or protein S deficiency.
• Purple toe syndrome: a rare complication causing painful, purplish discoloration of the toes due to cholesterol microembolization.
• Other: nausea, transient hair loss (alopecia), rash, and hypersensitivity reactions have been reported uncommonly.

Pregnancy

Unifarin is contraindicated in pregnancy because it is a well-established teratogen (can cause "fetal Unifarin syndrome," including nasal hypoplasia, stippled epiphyses, and central nervous system abnormalities) and can cause fetal or neonatal hemorrhage. The only exception is a small group of patients with mechanical heart valves at particularly high thromboembolic risk, where continued use may be considered strictly under specialist obstetric and cardiology supervision after full discussion of risks. Women of childbearing potential should use effective contraception during treatment.

Lactation

Unifarin is generally considered compatible with breastfeeding, as it does not pass into breast milk in clinically significant amounts and breastfed infants of mothers taking Unifarin do not typically show altered coagulation parameters. Nonetheless, use only under medical supervision, and consult a physician before breastfeeding while on this medicine.

Serious Bleeding Risk (Boxed Warning-Level Concern)

Unifarin can cause major or fatal bleeding. Regular INR (International Normalized Ratio) monitoring is essential in all patients throughout treatment to keep the anticoagulant effect within the intended therapeutic range. Bleeding risk is higher at INR values above the target range, and also increases with age, other bleeding risk factors, and interacting medicines (see Interactions).

Narrow Therapeutic Index

Unifarin has a narrow therapeutic index; small changes in dose, diet, other medicines, or clinical status can significantly alter anticoagulant effect. Do not start, stop, or change the dose of any other medicine, herbal product, or supplement without informing the physician managing Unifarin therapy.

Genetic Factors

Genetic variation (CYP2C9 and VKORC1 polymorphisms) can substantially affect individual dose requirements; some patients may require unusually low or high doses.

Other Precautions

• Use with caution in hepatic impairment (can potentiate effect) and in the elderly (increased sensitivity and bleeding risk).
• Falls, trauma, and activities with high bleeding/injury risk should be minimized.
• Avoid intramuscular injections, and use caution with invasive procedures, while on treatment.
• Alcohol use should be limited, as it can affect Unifarin metabolism and bleeding risk.

Overdose of Unifarin presents primarily as excessive anticoagulation, which may cause bleeding manifestations such as bruising, blood in urine or stool, prolonged bleeding from cuts, gum or nose bleeding, or in severe cases, internal or intracranial hemorrhage.

Any suspected overdose or signs of significant bleeding require immediate medical attention — contact a physician, emergency services, or poison control right away. Reversal of excessive anticoagulation (with vitamin K and, in severe bleeding, agents such as prothrombin complex concentrate or fresh frozen plasma) must be carried out under direct medical supervision; do not attempt home treatment or self-manage a suspected overdose.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

• Pediatric use: Unifarin may be used in children for specific thromboembolic conditions under the close supervision of a pediatric specialist experienced in anticoagulation, with weight-based initial dosing and INR-guided adjustment. Safety and efficacy for routine, unsupervised use in children have not been as extensively established as in adults.
• Elderly: Older patients are generally more sensitive to the anticoagulant effect and have a higher bleeding risk; lower initiation doses and closer INR monitoring are recommended.
• Hepatic impairment: Hepatic dysfunction can potentiate the response to Unifarin (reduced synthesis of clotting factors and impaired drug metabolism); use with caution and monitor INR closely.
• Renal impairment: No specific dose adjustment is generally required based on renal function alone, but bleeding risk may be increased in significant renal impairment; monitor closely.

Duration of Unifarin therapy depends on the indication and is determined by the prescribing physician:

• Provoked venous thromboembolism (with a reversible risk factor): typically about 3 months.
• Unprovoked or recurrent venous thromboembolism, or ongoing risk factors: longer-term or indefinite therapy may be recommended.
• Atrial fibrillation with continued stroke risk: usually long-term, often lifelong therapy.
• Mechanical heart valves: typically lifelong therapy.

Treatment duration should never be shortened or extended without medical advice, and therapy should not be stopped abruptly without consulting the physician.

Anticoagulants; Vitamin K antagonists

Warfarin acts by inhibiting vitamin K epoxide reductase complex 1 (VKORC1) in the liver, blocking the recycling of vitamin K to its active form. This reduces the availability of vitamin K needed to synthesize functional clotting factors II, VII, IX, and X, and the natural anticoagulant proteins C and S, thereby producing an anticoagulant effect that develops over several days and reverses gradually after the drug is stopped.

X

Use of Unifarin in children is reserved for specific thromboembolic conditions (e.g., certain congenital heart defects, mechanical valves, or thrombosis) and should only be undertaken under the supervision of a pediatric hematology/cardiology specialist experienced in anticoagulant management. Dosing is weight-based initially and then individualized entirely according to INR response, which can be more variable in children than adults. Safety and efficacy for indications and dosing regimens not specifically studied in children have not been established; routine, unsupervised pediatric use is not appropriate.